Emicizumab promotes factor Xa generation on endothelial cells
Journal of Thrombosis and Haemostasis · 2024
DOI: 10.1016/j.jtha.2024.02.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Ammon M Fager und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hematology/Oncology Service, Department of Veterans Affairs Medical Center, Durham, North Carolina, USA; Division of Hematology, Department of Medici…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Blood Coagulation Factors, Endothelial Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: BLRD VA, US Department of Veterans Affairs, Takeda Pharmaceuticals USA Inc.
Abstract (Originalsprache)
BACKGROUND: Until recently, the treatment of hemophilia A relied on factor (F)VIII replacement. However, up to one-third of patients with severe hemophilia A develop neutralizing alloantibodies that render replacement therapies ineffective. The development of emicizumab, a bispecific antibody that partially mimics FVIIIa, has revolutionized the treatment of these patients. However, the use of an activated prothrombin complex concentrate [FEIBA (Takeda)] to treat breakthrough bleeding in patients on emicizumab has been associated with thrombotic complications including a unique microangiopathy. OBJECTIVES: We hypothesized that the thrombotic complications observed with the combination of emicizumab and FEIBA might be due to excessive expression of procoagulant activity on the surface of endothelial cells. METHODS: We examined the ability of emicizumab to promote FX activation on endothelial cells using 2 cell culture models. RESULTS: We found that endothelial cells readily support emicizumab-mediated activation of FX by FIXa. The level of FXa generation depends on the concentration of available FIXa. The addition of FEIBA to emicizumab increased FXa generation in a dose-dependent manner on endothelial cells in both models. The rate of FXa generation was further enhanced by endothelial cell activation. However, unlike emicizumab, we found limited FXa generation in the presence of FVIII(a), which followed a significant lag time and was not dependent on FIXa concentration under these conditions. CONCLUSION: Emicizumab promotes FXa generation on the surface of endothelial cells, which is markedly enhanced in the presence of FEIBA. These findings demonstrate a potential mechanism for the thrombotic complications seen with the combined use of emicizumab and FEIBA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology/Oncology Service, Department of Veterans Affairs Medical Center, Durham, North Carolina, USA; Division of Hematology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA. E…
- Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Department of…
- Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Pathology and Laboratory Medicine Service, Department of Veterans Affairs Medical Center, Durham, North Carolina, USA; Department of Pathology, Duke University School of Medicine, Durham, North Carolina, USA.
Förderung
- BLRD VA
- US Department of Veterans Affairs
- Takeda Pharmaceuticals USA Inc
- Novo Nordisk A/S
Zitieren
APA
Fager, A. M., Ellsworth, P., Key, N. S., Monroe, D. M., & Hoffman, M. (2024). Emicizumab promotes factor Xa generation on endothelial cells. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.02.017
Vancouver
Fager AM, Ellsworth P, Key NS, Monroe DM, Hoffman M. Emicizumab promotes factor Xa generation on endothelial cells. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.02.017
BibTeX
@article{Fager2024,
author = {Fager, Ammon M and Ellsworth, Patrick and Key, Nigel S and Monroe, Dougald M and Hoffman, Maureane},
title = {Emicizumab promotes factor Xa generation on endothelial cells},
journal = {Journal of Thrombosis and Haemostasis},
year = {2024},
doi = {10.1016/j.jtha.2024.02.017}
}
EUVIMED